<DOC>
	<DOCNO>NCT01786018</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival , transplant-related morbidity ( TRM ) day +100 +365 , overall survival incidence acute chronic GVHD refractory/early relapse aggressive B-cell non Hodgkin lymphoma patient treat allogeneic Transplantation conditioning Thiotepa , Busulfan fludarabin .</brief_summary>
	<brief_title>Thiotepa , Busulfan Fludarabin pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas</brief_title>
	<detailed_description>In present study , hypothesise patient aggressive B cell lymphomas refractory relapse early ( within 12 month ) completion standard first-line immunoProtocol TBF2012 Version 1 , 20 Nov 2012 9 chemotherapy benefit de-bulking salvage therapy ( i.e . R-DHAP + bortezomib ) follow allograft improve progression-free survival . Patient inclusion criterion - Patients refractory/relapsed aggressive B-cell non Hodgkin lymphomas frontline therapy . - Patients stable disease partial complete remission ( PET-negative ) salvage therapy - Patients young 65 year old - A fully HLA-identical sibling match unrelated donor available . Patients one antigen mismatch donor consider - Patient must competent give consent Patient exclusion criterion - Patients treat autologous transplant salvage therapy - Patients progressive lymphomas despite conventional therapy - Patients progressive lymphomas despite conventional therapy - Uncontrolled CNS involvement disease - Fertile men woman unwilling use contraceptive technique 12 month follow treatment - Females pregnant breastfeed - Organ dysfunction define follow : - Cardiac function : ejection fraction &lt; 30 % uncontrolled cardiac failure - Pulmonary : DLCO &lt; 40 % predict - Liver function abnormality : elevation bilirubin &gt; 3 mg/dl and/or transaminases &gt; 4 upper limit normal - Renal : creatinine clearance &lt; 50 cc/min ( 24 hour urine Protocol TBF2012 Version 1 , 20 Nov 2012 6 collection ) - Karnofsky performance score &lt; 60 % - Patients poorly control hypertension despite multiple antihypertensive - Documented fungal disease progressive despite treatment - Viral infection : HIV positive patient . - Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HBV DNA test perform positive subject exclude . - Positive serology hepatitis C ( HC ) define positive test HCAb , case reflexively perform HC RIBA immunoblot assay sample confirm result - Psychiatric disorder psychosocial problem opinion primary physician Principal Investigator would place patient unacceptable risk regimen . - Patients active non-hematologic malignancy ( except nonmelanoma skin cancer ) . - Patients history non-hematologic malignancy ( except non-melanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence . Donor inclusion criterion : - Related unrelated HLA identical donor good health contra-indication donation . One antigen HLAmismatched ( 9/10 match ) donor also consider . - No contra-indication donor collection apheresis mononuclear cell mobilize G-CSF dose 10-12 μg/kg body weight . - Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) . Donor exclusion criterion : - Age &lt; 18 year . - Identical twin . - Pregnancy . - Infection HIV . - Inability achieve adequate venous access . - Known allergy filgrastin ( G-CSF ) . - Current serious systemic illness . Donor inclusion criterion : - Related unrelated HLA identical donor good health contra-indication donation . One antigen HLAmismatched ( 9/10 match ) donor also consider . - No contra-indication donor collection apheresis mononuclear cell mobilize G-CSF dose 10-12 μg/kg body weight . - Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) . Donor exclusion criterion : - Age &lt; 18 year . - Identical twin . - Pregnancy . - Infection HIV . - Inability achieve adequate venous access . - Known allergy filgrastin ( G-CSF ) . - Current serious systemic illness . Donor inclusion criterion : - Related unrelated HLA identical donor good health contra-indication donation . One antigen HLAmismatched ( 9/10 match ) donor also consider . - No contra-indication donor collection apheresis mononuclear cell mobilize G-CSF dose 10-12 μg/kg body weight . - Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) . Donor exclusion criterion : - Age &lt; 18 year . - Identical twin . - Pregnancy . - Infection HIV . - Inability achieve adequate venous access . - Known allergy filgrastin ( G-CSF ) . - Current serious systemic illness .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patient inclusion criterion : Patients refractory/relapsed aggressive Bcell non Hodgkin lymphomas frontline therapy . Patients stable disease partial complete remission ( PETnegative ) salvage therapy Patients young 65 year old A fully HLAidentical sibling match unrelated donor available . Patients one antigen mismatch donor consider Patient must competent give consent . Patient exclusion criterion : Patients treat autologous transplant salvage therapy Patients progressive lymphoma despite conventional therapy Patients progressive lymphoma despite conventional therapy Uncontrolled CNS involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant breastfeeding Organ dysfunction define follow : Cardiac function : ejection fraction &lt; 30 % uncontrolled cardiac failure Pulmonary : DLCO &lt; 40 % predict Liver function abnormality : elevation bilirubin &gt; 3 mg/dl and/or transaminases &gt; 4x upper limit normal Renal : creatinine clearance &lt; 50 cc/min ( 24 hour urine collection ) Karnofsky performance score &lt; 60 % Patients poorly control hypertension despite multiple antihypertensive Documented fungal disease progressive despite treatment Viral infection : HIV positive patient . Positive serology Hepatitis B ( HB ) define positive test HBsAg . In addition , negative HBsAg HBcAb positive ( regardless HBsAb status ) , HBV DNA test perform positive subject exclude . Positive serology hepatitis C ( HC ) define positive test HCAb , case reflexively perform HC RIBA immunoblot assay sample confirm result Psychiatric disorder psychosocial problem opinion primary physician Principal Investigator would place patient unacceptable risk regimen . Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) . Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence . Donor inclusion criterion : Related unrelated HLA identical donor good health contraindication donation . One antigen HLAmismatched ( 9/10 match ) donor also consider . No contraindication donor collection apheresis mononuclear cell mobilize GCSF dose 1012 mg/kg body weight . Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) . Donor exclusion criterion : Age &lt; 18 year . Identical twin . Pregnancy . Infection HIV . Inability achieve adequate venous access . Known allergy filgrastin ( GCSF ) . Current serious systemic illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Non Hodgkin lymphoma</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Fludarabin</keyword>
</DOC>